摘要
虽然近年来乳腺癌的药物治疗获得了显著的进展,然而对于个体化治疗我们还所知甚少。作为公认的预后因子纳入治疗指南中的ER、PR和HER-2三项指标已经成为制定患者治疗方案时最重要的预测指标。随着对三阴乳腺癌和三阳乳腺癌的不断深入了解,我们意识到这三项指标之间复杂的交互作用不但影响一些特殊亚型的临床表现,而且与患者的预后以及治疗选择密切相关。
Although recent progress in drug therapy has facilitated marked advances in chemotherapy for breast cancer, little has been achieved in the development of individualized chemotherapy. Prognostic factors such as estrogen receptor, progesterone receptor, and human epidemal growth factor receptor 2 have recently been incorporated into risk classification in the guidelines as predictive factors for treatment response, indicating that the treatment decisions for breast cancer have shifted to factors prediction of treatment response. With the increasing understanding of triple-negative and triple-positive breast cancer, the complex interactions among the three essentials have been believed to be related to not only the clinical behaviors of several subtypes of breast cancer, but also the decisions of individualized therapy and prognosis of individuals for the physicians.
出处
《临床肿瘤学杂志》
CAS
2010年第2期97-100,共4页
Chinese Clinical Oncology
基金
2006年上海市科委科研计划资助项目(06DZ19505)
关键词
雌激素受体
孕激素受体
表皮生长因子受体2
个体化治疗
Estrogen receptor（ER）
Progesterone receptor（PR）
Epidemal growth factor receptor 2 （HER-2）
Individualized therapy
